VSTM vs VYNE

Verastem, Inc. vs VYNE Therapeutics Inc. — Valuation Comparison 2026

VSTM

Pharmaceutical Preparations
Verastem, Inc.
Quality
5.8
out of 10
Value Trap
24
SAFE
Price
$4.33
Last close
Models
8/13
Active
VS

VYNE

Pharmaceutical Preparations
VYNE Therapeutics Inc.
Quality
4.6
out of 10
Value Trap
32
LOW
Price
$0.68
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType VSTM Fair ValueVSTM Upside VYNE Fair ValueVYNE Upside
Bayesian DCF Intrinsic $2.16 -50.2% $0.58 -14.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.19 -49.3% $2.33 +242.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VSTM vs VYNE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VSTM vs VYNE — Which Stock Is More Undervalued?

VSTM scores higher with a 5.8/10 quality rating vs VYNE's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Verastem, Inc. (VSTM) and VYNE Therapeutics Inc. (VYNE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VSTM currently trades at $4.33 with a QOC of 5.8/10, while VYNE trades at $0.68 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).